 Tricida Inc., a clinical-stage pharmaceutical company working on a kidney disease drug, has filed for Chapter 11 bankruptcy protection in Delaware, with roughly US350 million of debt, according to a court filing. The San Francisco-based company will try to sell itself out of bankruptcy and has signed a restructuring support agreement RSA with 80 of its convertible noteholders, according to court papers. 